Comparison of Dissolution Profiles and Serum Concentrations of Two Lamotrigine Tablet Formulations

Mladena Lalic,¹ Ana Pilipovic,¹ Svetlana Golocorbin-Kon,¹ Ksenija Gebauer-Bukurov,² Ksenija Bozic,² Momir Mikov^{3,4} and Jelena Cvejic¹

1 Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Novi Sad, Republic of Serbia

2 Institute of Neurology, Clinical Centre of Vojvodina, University of Novi Sad, Novi Sad, Republic of Serbia

3 School of Pharmacy, University of Otago, Dunedin, New Zealand

4 Department of Pharmacology, Toxicology and Clinical Pharmacology, University of Novi Sad, Novi Sad, Republic of Serbia

Abstract

Background: Since 2005, the antiepileptic drug lamotrigine has been present in the market in various generic products, in addition to the original brand of Lamictal®. The linear pharmacokinetics and wide therapeutic window of lamotrigine enable seizure-free patients to easily switch from brand to generic antiepileptic drugs.

Objective: The aim of this study was to investigate the extent of variations in lamotrigine serum concentrations between two immediate-release tablet formulations. Data were compared with *in vitro* difference and similarity tests on dissolution profiles of the two formulations.

Methods: Dissolution characteristics of formulations A (reference) and B (test) were evaluated at three points spanning the physiologic pH range (pH 1.2, pH 4.5, pH 6.8). A model-independent approach of difference (*f*1) and similarity (*f*2) tests were applied to dissolution data. A clinical study was performed with 16 patients who were divided into two groups – one group received formulation A (*n*=9) and the other received formulation B (*n*=7). Lamotrigine steady-state concentrations were determined by high-performance liquid chromatography on a reverse-phase column.

Results: There were no statistically significant differences in lamotrigine serum concentrations between the two groups, although formulation B had slightly higher mean concentration values (formulation A: 3.97 ± 4.1 µg/mL; formulation B: 5.78 ± 2.7 µg/mL). Dissolution profiles of the two formulations were similar in the pH 1.2 dissolution medium; however, the dissolution profiles of formulation B were outside the dissolution limit ($\geq 85\%$ at 15 minutes) in the pH 4.5 and 6.8 dissolution media.

Conclusions: No significant changes in the serum concentrations of lamotrigine were seen between the two investigated formulations. There is no

evidence to suggest that the differences in dissolution profiles at pH 4.5 and pH 6.8 affect the therapeutic efficacy of the formulations. It is evident that the doses of test formulation given to the patients were higher as a consequence of common assumption that generic products have a lower absorption rate, which is proven unnecessary in this study. This investigation was a pilot study and thus further investigations with a larger sample size are necessary to determine if there is a connection between dissolution profiles and the therapeutic effect of investigated formulations.

Introduction

Epilepsy is a chronic disease that often requires life-long antiepileptic drug (AED) treatment. The primary goal of AED treatment is the avoidance of seizures with no or minimal adverse effects.^[1] When long-term seizure remission has been achieved, even a single breakthrough seizure can have serious clinical and social consequences.^[2-8] Healthcare systems tend to favor the use of generic drugs in order to reduce medical costs, despite a number of potential disadvantages of generic drugs.^[2,9] In the treatment of epilepsy, generic formulations of AEDs are widely used. Although generic substitution of AEDs may be appropriate for many patients, there appear to be a substantial number of patients in whom generic substitution may represent a suboptimal level of care. Issues related to AEDs that should be taken into consideration include their insolubility in water, narrow therapeutic index, non-linear pharmacokinetic profiles, and potential for adverse events. However, breakthrough seizures or adverse reactions due to generic substitution have been reported for AEDs with linear pharmacokinetic profiles and wide therapeutic ranges, such as lamotrigine.^[9,10]

After the expiration of the patent on the original product (Lamictal®) on 1 June 2005, it became possible in Serbia to market generic products containing lamotrigine. The linear pharmacokinetics and wide therapeutic window of lamotrigine^[11] enable seizure-free patients to easily switch from brand to generic AEDs.

Lamotrigine is in class II of the biopharmaceutical system of classification (BSC). After oral administration, lamotrigine is rapidly ab-

sorbed with an absolute bioavailability of 98%.^[12-14] Lamotrigine is a weak base (dissociation constant $pK_a = 5.5$), is poorly soluble in water (0.17 mg/mL at 25°C), with a log octanol/water partition coefficient (log P) of 1.19 at pH 7.6.^[15] Absorption of lamotrigine after oral tablet administration depends on the release of the drug substance from the drug product, and hence, the dissolution or solubility of the drug under physiologic conditions. Because of the critical nature of these steps, *in vitro* dissolution may be relevant to the prediction of *in vivo* performance. Generic tablets of lamotrigine contain different substances to branded tablets, which may affect the release and pharmacokinetics of the active substance. Big differences between lamotrigine preparations could cause relapses in seizure-free patients or toxic reactions.

Although studies of bioequivalence in different lamotrigine tablet formulations are conducted, they are performed in healthy subjects and not in patients. The patient population is likely to have greater variability in terms of characteristics.^[16] For example, patients with epilepsy are likely to span a larger age range than the adults used in standard tests, which may result in differences in drug-handling characteristics.^[17] In addition, only single-dose studies are performed, which are not relevant to the continued use of AEDs. If one product is bioequivalent to another, that does not guarantee that a drug will have the same therapeutic and adverse effect profile as the reference drug.^[2,18] It is not yet known whether absorption rates between different lamotrigine tablet formulations are the same. Some studies have shown that differences in absorption rates correlate with dose-dependent adverse effects.^[19,20]

In this study, the extent of variations in lamotrigine serum concentrations between two immediate-release tablet formulations was investigated. Data were correlated with *in vitro* difference and similarity tests on dissolution profiles of the two formulations.

Materials and Methods

Clinical Study

This study was approved by the Medical Faculty Ethics Committee at the University of Novi Sad, Novi Sad, Republic of Serbia. Written informed consent was obtained from all patients or their guardians. Demographic data were collected from all patients. Enrollment criteria included epileptic patients who were receiving lamotrigine monotherapy (i.e. formulation A: Lamictal® 100 mg tablets [GlaxoSmithKline, UK, Lot: 062656, expiry date: 07.2010]; or formulation B: Lamal® 100 mg tablets [Alkaloid, Skoplje, Macedonia, Lot: 07593 0308, expiry date: 03.2011]) and had not missed a dose for 3 weeks prior to enrollment (i.e. only patients with steady-state lamotrigine were included). Individual lamotrigine doses that were optimal for seizure control ranged from 50 to 300 mg/day, and were taken 30 minutes before breakfast and 30 minutes before the evening meal as instructed by investigators. Seizure control and dose-related CNS adverse effects (e.g. dizziness, ataxia, diplopia, blurred vision, nausea, and vomiting) were investigated in all patients. Patients were divided into two main groups. The first group consisted of patients taking formulation A (n=9), while the second group consisted of patients taking formulation B (n=7). All patients were initially receiving formulation A, before the seven patients were switched to formulation B for cost-saving reasons; treatment with formulation A cost €4, but formulation B cost only 20c because it was subsidized by the healthcare system. Patients were treated for at least 6 months with formulation A or formulation B before the pharmacokinetic study. Both formulations were taken twice a day. During the study, blood samples were taken from each patient once a day. Patients were asked to

report precisely the time of drug administration, and blood samples were collected accordingly. The time between drug administration and sample collection was between 1.5 and 8 hours. All statistical calculations were performed using SPSS® version 17 (Chicago, IL, USA). Statistical significance was tested by Student's t-test. A p-value of <0.05 was considered significant.

Dissolution Testing and Sample Preparation

In vitro dissolution of formulations A and B was performed according to the published method.^[21] The dissolution test was performed by using Erweka dissolution apparatus (Erweka, DT800, Germany). Three dissolution media (900 mL) were used over the physiologic pH range of 1.2–6.8 (pH 1.2 HCl solution, pH 4.5 acetate buffer, pH 6.8 phosphate buffer), with six tablets being analyzed for each medium. The paddle assembly was used (USP apparatus 2), revolution speed was kept at 50 rpm. In all experiments, 5 mL of dissolution sample was withdrawn at 5, 10, 15, 30, 45, and 60 minutes. 5 mL of fresh medium were replaced after sampling. Experiments were conducted in triplicate (i.e. a total of 18 tablets tested per medium). Samples were filtered through a 0.45 µm porosity filter. 100 µL of the filtered solution was diluted with 900 µL of mobile phase solution used for high-performance liquid chromatography (HPLC) analysis. 20 µL of each sample was then injected into the HPLC system.

Chromatographic Conditions for Dissolution Samples

Chromatographic separation was performed on an HPLC system (Agilent Technology Series 1100, USA), which consisted of an autoinjector, a C18 guard column (4.6 × 12.5 mm, 5 µm, Zorbax, Agilent Technology, USA), a C18 analytical column (4.6 × 250 mm, 5 µm, Zorbax, Agilent Technology, USA), and a diode-array detector (DAD) [210 nm]. The mobile phase solution was a mixture of phosphate buffer (0.05 mol/L, adjusted to pH 2.68 with 40% ortho-phosphoric acid) and acetonitrile (68:32, v/v). All separations were performed isocratically at a flow rate of 1.2 mL/min.

Table I. Dissolution tests of formulation A (original lamotrigine formulation) and formulation B (generic lamotrigine formulation) in three different pH media (pH 1.2 HCl solution, pH 4.5 acetate buffer, and pH 6.8 phosphate buffer)

Time (min)	Dissolution (%) [± SD]					
	pH 1.2		pH 4.5		pH 6.8	
	A	B	A	B	A	B
5	95.13±4.84	90.20±5.32	87.98±1.55	70.44±5.82	69.74±1.32	59.55±4.17
10	99.34±2.19	95.61±2.51	87.34±2.18	75.82±2.66	83.53±1.30	62.84±3.06
15	100.69±3.14	97.52±3.98	96.48±1.28	79.91±5.17	95.06±1.91	65.98±2.46
30	100.84±3.14	98.43±2.82	98.77±3.21	80.72±2.98	97.55±3.97	67.32±3.15
45	100.31±3.24	100.1±4.11	98.79±4.40	85.78±4.44	99.72±1.28	71.41±2.27
60	100.77±2.92	100.66±3.40	99.6±2.50	86.91±4.49	100.86±2.45	71.01±2.14

Blood Sample Preparation

Blood samples were collected in non-heparinized tubes and centrifuged at 3000 rpm for 15 minutes. Serum was separated, transferred into test tubes and stored at -20°C prior to analysis. Before chromatographic analyses, one part of serum was mixed with two parts of acetonitrile, centrifuged at 5000 rpm for 10 minutes. The supernatant (10 µL) was injected into the HPLC system.

Chromatographic Conditions for Serum Samples

Serum samples were analyzed for lamotrigine concentrations at steady state using a published method and the same HPLC system as for dissolution samples.^[22] The mobile phase solution was a mixture of potassium dihydrogen phosphate buffer (10 mmol/L, adjusted to pH 7 using 0.5 mol/L NaOH), methanol, acetonitrile, and acetone (55:22:12:11 v/v). The flow rate was 1.2 mL/min. Under these conditions, retention time for lamotrigine was 4.3 minutes. The calibration curve was linear over the concentration range of 0.5–40 µg/mL of lamotrigine, with a coefficient of determination (r²) of ≥0.989.

Results

In Vitro study

In vitro dissolution of formulations A and B was performed to obtain information about possible differences between their dissolution profiles and, consequently, differences in bioavailability.

Cumulative percentages of the drug dissolved from the tablets were calculated over experimentally obtained drug content. Results of the dissolution tests are shown in table I, and dissolution profile curves in figures 1 and 2.

The fastest dissolution rate of drug was obtained at pH 1.2 for both formulations because lamotrigine has the highest solubility in this medium. The pH value of the medium had a marked effect on the dissolution profile of formulation B, while formulation A had similar profiles in all three media, which is in accordance with previously reported results.^[21] The dissolution limit that was set at ≥85% at 15 minutes by the USP (XXVIII) was not fulfilled for formulation B in pH 4.5 and pH 6.8 media (figure 2, table I).^[23]

Fig. 1. Dissolution profile of formulation A (original formulation) in three different pH media (pH 1.2 HCl; pH 4.5 acetate buffer; pH 6.8 phosphate buffer).

Fig. 2. Dissolution profile of formulation B (generic formulation) in three different pH media (pH 1.2 HCl; pH 4.5 acetate buffer; pH 6.8 phosphate buffer).

Difference and Similarity Test

A model-independent approach of difference (*f*₁) and similarity (*f*₂) tests were applied to dissolution data. The values of *f*₁ and *f*₂ factors for the test product (formulation B) versus the reference (formulation A) were calculated from the means of the percentage of drug dissolved at each timepoint (table I) by using equations 1 and 2.^[24]

$$f_1 = \left\{ \frac{\left[\sum_{i=1}^n |R_i - T_i| \right]}{\left[\sum_{i=1}^n \frac{R_i + T_i}{2} \right]} \right\} \times 100 \tag{Eq. 1}$$
$$f_2 = 50 \times \log \left\{ \left[1 + \left(\frac{1}{n} \right) \sum_{i=1}^n (R_i - T_i)^2 \right]^{-0.5} \right\} \times 100 \tag{Eq. 2}$$

where *n* is the number of dissolution sample times, and *R_i* and *T_i* are the individual or mean percentage of drug dissolved at each timepoint (*t*), for the reference and test dissolution profiles, respectively. According to the US FDA guidance, *f*₁ values generally vary between 0 and 15, and *f*₂ values vary between 50 and 100, ensuring equivalence of the dissolution curves.^[25] Dissolution profiles of formulations A and B were only similar in the pH 1.2 medium (table II).

Clinical Study

The dissolution data were compared with clinical data of randomly chosen patients receiv-

ing monotherapy with formulation A (*n*=9 [*n*=5 females, *n*=4 males]) or formulation B (*n*=7 [*n*=3 females, *n*=4 males]). Dosage details and patient characteristic are shown in table III.

There was a statistically significant difference between serum concentrations of lamotrigine in patients receiving formulation A ($3.14 \pm 1.95 \mu\text{g/mL}$) compared with formulation B ($5.78 \pm 2.78 \mu\text{g/mL}$) [figure 3a]. The range of lamotrigine serum concentrations was between 1.03 and 7.44 $\mu\text{g/mL}$ for formulation A, and between 1.03 and 9.44 $\mu\text{g/mL}$ for formulation B. Most patients receiving formulation A had plasma concentrations of lamotrigine <3 $\mu\text{g/mL}$ (five of nine). However, the majority of lamotrigine plasma concentrations (six of seven) in patients receiving formulation B were in the range of 3 to 14 $\mu\text{g/mL}$, which has previously been suggested as the therapeutic range.^[26,27] No dose-dependent adverse effects appeared in the patients, and all patients were seizure free. No statistically significant differences were found between dose-normalized concentrations of these two formulations (figure 3b).

The relationship between lamotrigine serum concentration ($\mu\text{g/mL}$) and lamotrigine dose (mg/kg/day) were linear in both formulations ($r^2=0.78484$ formulation A; $r^2=0.83417$ formulation B) [figure 4]. Formulation A had a lower standard deviation (SD) and data scattering because, as the dissolution data showed, it is less influenced by pH changes. The test formulation, or formulation B, had a higher data scattering and SD, which corresponds with the higher influence of pH changes on the dissolution profile.

Discussion

This study showed that the investigated lamotrigine tablet formulations have different dissolution

Table II. Difference (*f*₁) and similarity (*f*₂) factors for reference (formulation A – original formulation) vs test product (formulation B – generic formulation)

Dissolution medium	Difference factor (<i>f</i> ₁)	Similarity factor (<i>f</i> ₂)
pH 1.2 HCl solution	2.46	74.99
pH 4.5 acetate buffer	17.05	40.86
pH 6.8 phosphate buffer	31.41	29.43

Table III. Dosing details of lamotrigine and summary of patients characteristics for formulation A (original formulation) and formulation B (generic formulation)^a

	Formulation A	Formulation B
No. of patients	9	7
Dosing details		
dose of lamotrigine (mg/kg/day)	2.02 ± 0.85*	2.94 ± 1.52*
lamotrigine serum concentration (µg/mL)	3.14 ± 1.95*	5.78 ± 2.78*
lamotrigine dose-normalized concentration	1.68 ± 0.99*	2.35 ± 2.04*
Characteristics		
age (y)	27.11 ± 5.86	25.86 ± 12.88
height (cm)	176.33 ± 9.91	172.00 ± 5.23
weight (kg)	71.33 ± 14.92	64.57 ± 7.52

a Data are given as mean ± SD.

* p < 0.05.

profiles because they differ in the manufacturing process used and in the substances with which the active principle is associated.^[28] These differences have influences on the dissolution rates in the gastrointestinal tract, as well as absorption, and, hence, the bioavailability of lamotrigine.

Results of the dissolution tests were in correlation with the chemical properties of lamotrigine. As a basic drug, lamotrigine had high solubility only in pH 1.2 HCl medium,^[29] thus, the dissolution profiles were similar only in acid medium. According to some investigations, there is good correlation on level A between *in vitro* and *in vivo* data of lamotrigine.^[29] Lamotrigine is in class II of the BSC and its dissolution is the rate-limiting step for absorption and bioavailability of this drug.^[29,30] *In vitro* data indicated that dissolution media had an impact on the dissolution profiles of these two formulations in two of the three different pH media. Thus, the variations in lamotrigine serum concentrations within patients receiving these products was due to the fact that the main dissolution and absorption should take place in the stomach environment. According to some studies, after ingestion of drug in the fasted state, with about 200 mL of water, the pH in the stomach can rise up to 4.5, and it needs about 60 minutes to return to the equilibrium of pH 1.2. With ingestion of food (i.e. fed state), the stomach pH could rise up to 7, and it takes more than 90 minutes to reach equilibrium.^[31] Since the content of the stomach in the fasted state is

Fig. 3. (a) Lamotrigine (LTG) serum concentrations (Cs); and (b) dose-normalized concentrations of formulations A (original formulation) and B (generic formulation) [*'10' represents an extreme case and '16' is an outlier value].

Fig. 4. Lamotrigine (LTG) serum concentrations (Cs) vs LTG daily dose.

emptied every 15 minutes and in the fed state every 30–60 minutes, observed statistical differences in serum concentrations of the two tested formulations is justified.

Patients receiving formulation B actually received a higher lamotrigine dose than those treated with formulation A, although there were no statistically significant differences between doses.

It is a common assumption that generic drugs have a lower absorption rate and therapeutic efficiency than branded drugs and therefore patients are given higher doses of generic drugs, which is proven unnecessary in this investigation. The variation in plasma concentrations could also be due to individual characteristics of patients (i.e. autoinduction and race), but they are unlikely to be clinically significant.^[32] There is no evidence to suggest that concentration variations of lamotrigine were caused by the differences in formulations.

Although switching of phenytoin, carbamazepine, and valproate is restricted in many countries, switching between lamotrigine products in most European countries is permitted. However, in some countries, such as Sweden, it is specified that lamotrigine products cannot be replaced with one another, since breakthrough seizures or adverse reactions due to substitution

have been reported.^[9,10,33] This pilot study supports evidence for the ability to switch between lamotrigine immediate-release tablet products with no consequences on the health of the patient.

Conclusions

Although dissolution profiles of the two formulations are only similar in the pH 1.2 medium, switching between formulations A and B did not cause any dose-dependent adverse events and worsening of seizure control. Taking into consideration that five of nine patients receiving formulation A had serum concentrations of lamotrigine that were under the proposed therapeutic range, and this was only one in seven in formulation B, there is no evidence to support the fact that therapeutic efficacy of formulation B is lower because its dissolution profile was out of specification in pH 4.5 and pH 6.8 media. This pilot study supports evidence for the ability to switch between these two lamotrigine tablet formulations.

Acknowledgments

This study has been supported by project no. 145060 of the Ministry of Science and Technology, Republic of Serbia. The authors have declared that they have no conflicts of interest that are directly relevant to the content of this article.

References

1. EUCARE. European white paper in epilepsy. *Epilepsia* 2003; 44 (6): 1-88
2. Besag FMC. Is generic prescribing acceptable in epilepsy? *Drug Safety* 2000; 23: 173-82
3. Kramer G, Schneble H, Wolf P. Risks of the new "aut idem" regulations for treatment with antiepileptic drugs. *Akt Neurol* 2002; 29: 115-22
4. Jacoby A, Baker G, Steen N, et al. The clinical course of epilepsy and its psychosocial correlate: findings from a UK community study. *Epilepsia* 1996; 37: 148-61
5. Crawford P, Hall WW, Chappell B, et al. Generic prescribing for epilepsy: is it safe? *Seizure* 1996; 5: 1-5
6. Anonymous. For and against generic prescribing. *Drug Ther Bull* 1987; 25: 93-5
7. Meyer MC, Straughn AB. Biopharmaceutical factors in seizure control and drug toxicity. *Am J Hosp Pharm* 1993; 50 (5): S17-22
8. Andermann F, Duh MS, Gosselin A, et al. Compulsory generic switches of antiepileptic drugs: high switchback rates

- to branded compounds compared with other drug classes. *Epilepsia* 2007; 48: 464-9
9. Blier P. Brand versus generic medications: the money, the patients and the research. *J Psychiatry Neurosci* 2003; 28: 167-8
 10. Markus GM, McCormick J. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. *Clin Ther* 2007; 29: 1249-50
 11. Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. *Clin Pharmacol Ther* 1987; 42: 535-41
 12. Levy RH, Mattson RH, Meldrum BS, et al. Antiepileptic drugs. 5th rev. ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2002
 13. Physicians' Desk Reference. Toronto (ON): Thomson PDR, 2007; 61: 1481-90
 14. Sweetman S. Martindale: the complete drug reference. London: Pharmaceutical Press, 2007
 15. Thaddeus HG, Fiedler-Kelly J, Cox E, et al. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. *J Clin Pharmacol* 1999; 39: 373-84
 16. Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? *Epilepsia* 2007; 48 (10): 1825-32
 17. Meredith PA. Generic drugs: therapeutic equivalence. *Drug Saf* 1996; 15: 233-42
 18. Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. *Epilepsy Behav* 2004; 5: 995-8
 19. Kramer G, Biraen A, Carreno M, et al. Current approaches to the use of generic antiepileptic drugs. *Epilepsy Behav* 2007; 11: 46-52
 20. Nielsen KA, Dahl M, Tommerup E, et al. Comparative daily profile with different preparations of lamotrigine: a pilot investigation. *Epilepsy Behav* 2008; 13: 127-30
 21. Sripalakit P, Srichaiya A, Kandee R. Development and validation of a HPLC method for a dissolution test of lamotrigine tablets and its application to drug quality control studies. *J Liquid Chromatography & Related Technologies* 2008; 31: 926-39
 22. Patil KM, Bodhankar SL. Simultaneous determination of lamotrigine, phenobarbitone, carbamazepine and phenytoin in human serum by high-performance liquid chromatography. *J Pharmaceut Biomed* 2005; 39: 181-6
 23. United States Pharmacopoeial Convention. The United States Pharmacopoeia. 28th ed. Rockville (MD) 2005
 24. Paul C, Sousa Lobo JM. Modeling and comparison of dissolution profiles. *Eur J Pharm Sci* 2001; 13: 123-33
 25. Guidance for Industry. Dissolution testing of immediate release solid oral dosage forms. Rockville (MD): U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 1997 Aug
 26. Morris RG, Black AB, Harris AL, et al. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of routine service. *Br Clin Pharmacol* 1998; 46: 547-51
 27. Lalic M, Cvejic J, Popovic J, et al. Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. *Eur J Drug Metab Pharmacokinet* 2009; 34 (2): 93-9
 28. Guberman A, Corman C. Generic substitution for brand name antiepileptic drugs: a survey. *Can J Neurol Sci* 2000; 27: 37-43
 29. Souliman S, Blanquet S, Beyssac E, et al. A level A *in vitro/in vivo* correlation in fasted and fed states using different methods: applied to solid immediate release oral dosage form. *Eur J Pharm Sci* 2006; 27: 72-9
 30. Lue BM, Nielsen FS, Magnussen T, et al. Using biorelevant dissolution to obtain IVIC of solid dosage forms containing a poorly-soluble model compound. *Eur J Pharm Biopharm* 2008; 69: 648-57
 31. Shah HJ, Subbaiah G, Patel DM, et al. *In vitro-in vivo* correlation of modified release dosage form of lamotrigine. *Biopharm Drug Dispos* 2009; 30: 524-31
 32. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. *Br J Clin Pharmacol* 1997; 43: 457-65
 33. MPA (Läkemedelsverket) substitutable medical products. Medical Products Agency. Uppsala: Läkemedelsverket, 2006
-

Correspondence: Dr Jelena Cvejic, Medical Faculty, Department of Pharmacy, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Republic of Serbia.
E-mail: cvejic@hotmail.com